ステージIII-IVまたは再発性子宮内膜がんにおける通常の化学療法(パクリタキセルおよびカルボプラチン)への免疫療法薬ペンブロリズマブの追加試験
基本情報
- NCT ID
- NCT03914612
- ステータス
- 実施中(募集終了)
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 813
- 治験依頼者名
- National Cancer Institute (NCI)
概要
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs is better or worse than the usual approach for treatment of this cancer.
対象疾患
介入
依頼者(Sponsor)
実施施設 (4)
新潟大学医歯学総合病院
Niigata, Niigata, Japan
社会福祉法人恩賜財団済生会支部 広島県済生会 済生会呉病院
Kure, Hiroshima, Japan
埼玉医科大学国際医療センター
Saitama, Japan
愛媛大学医学部附属病院
Tōon, Ehime, Japan